Association of High Tumor Mutation Burden in Non–Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression LevelsBiagio Ricciuti, Mark M. Awad, Xinan Wang et al.|JAMA Oncology|2022Cited by 383
Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint InhibitionBarzin Y. Nabet, Maximilian Diehn, Mohammad Shahrokh Esfahani et al.|Cell|2020Cited by 360
SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic SarcomasNatasha Rekhtman, William D. Travis, Gregory J. Riely et al.|Journal of Thoracic Oncology|2019Cited by 307
Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancerDanish Memon, Matthew D. Hellmann, Adam J. Schoenfeld et al.|Cancer Cell|2024Cited by 177
Lesion-Level Response Dynamics to Programmed Cell Death Protein (PD-1) BlockadeJuan C. Osorio, Matthew D. Hellmann, Kathryn C. Arbour et al.|Journal of Clinical Oncology|2019Cited by 134